SEC Tracker
Get the app
WVE · XBRL financial data

Wave Life Sciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (WVE's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers29*1320—year only99817*38213
Research and development34*33404145*41434653*475154
General and administrative14*14141516*18181821*222525
Total operating expenses48*47555661*59616474*707679
Operating income (loss)(19)*(34)(35)(64)23*(50)(53)(56)(56)*(31)(74)(66)
Interest income—322—322—554
Other income (expense)1*0(0)03*0(0)00*(0)(0)(0)
Income tax expense (benefit)0*0000*0000*000
Net income (loss)(16)*(32)(33)(62)29*(47)(50)(54)(53)*(26)(69)(62)
Earnings per share, basic USD per share(0.15)*(0.24)(0.25)(0.47)—(0.29)(0.31)(0.32)(0.30)*(0.13)(0.34)(0.30)
Earnings per share, diluted USD per share(0.15)*(0.24)(0.25)(0.47)—(0.29)(0.31)(0.32)(0.30)*(0.13)(0.34)(0.30)
Weighted average shares, basic millions of shares111*129130133162*163164168180*200204204
Weighted average shares, diluted millions of shares110*129130133162*163164168180*200204204

Balance sheet

CSV

Fiscal quarters (WVE's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents200181154311302243208196602545368197
Marketable securities————————0——233
Marketable securities, non-current————————0——0
Accounts receivable210101—21010112
Total current assets235197172325320258224215615561508459
Property and equipment, net131212111010987776
Right-of-use asset232220191817151412113938
Total assets275235209359352288252241638584558508
Accounts payable131218131614151416192019
Accrued liabilities222352357556
Total current liabilities18616617317111187878695505155
Lease liability, non-current2524222018161411974039
Total liabilities22720220420913510910510911272105106
Accumulated deficit(1,025)(1,056)(1,089)(1,151)(1,122)(1,169)(1,219)(1,273)(1,326)(1,352)(1,422)(1,484)
Total stockholders' equity4025(3)142210172139125518512454402
Total liabilities and equity275235209359352288252241638584558508
Common shares outstanding (cover page) millions of shares122122125153153154159167188192197197

Cash flows

CSV

Fiscal quarters (WVE's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(16)*(32)(33)(62)29*(47)(50)(54)(53)*(26)(69)(62)
Net cash from operating activities(33)*(33)(27)*(46)*(44)*(63)(46)*(45)*(34)*(60)(54)*(60)*
Purchases of property and equipment0*00*0*0*00*0*(0)*01*0*
Net cash from investing activities(0)*(0)(0)*(0)*(0)*(0)(0)*(0)*0*(0)(123)*(111)*
Proceeds from issuing common stock59*140*0*————————
Net cash from financing activities94*151*204*35*412*33*440*30*0*
Net change in cash60*(19)(27)*157*(9)*(59)(35)*(12)*406*(57)(177)*(171)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Wave Life Sciences19713(60)*197.2M7.4 quarters 10-QSep 30, 2026
Geron6357(16)*642.5M4.0 quarters 10-QJun 30, 2026
Intellia Therapeutics1067.7(83)*140.1M5.3 quarters 10-QJun 30, 2026
Niagen Bioscience67302.8*79.1M— 10-QJun 30, 2026
Nurix Therapeutics720673616*109.2M— 10-QAug 31, 2026
Syndax Pharmaceuticals13683(27)*not reported11.9 quarters 10-QSep 30, 2026
CorMedix25710286*77.9M— 10-QJun 30, 2026
Merus36712(85)*75.8M7.5 quarters 10-QSep 30, 2025
Ardelyx461282.2*251.4M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.